NASDAQ · Financial Statements

Retension Pharmaceuticals Inc. (RTSN) Revenue, Earnings & Financial Statements

$11.41 NASDAQ: RTSN Market Cap $42.79M

Data as of Nov 17, 2026 close · Source: Financial Modeling Prep (methodology)

Full income statement, balance sheet, and cash flow statement for Retension Pharmaceuticals Inc. (RTSN), plus valuation and return ratios.

Annual financials are not yet available for this stock.

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield—
Quick Ratio4.69
Interest Coverage—
Return 1Y—
Return 3Y—
Return 5Y—

Revenue and earnings of other Medical - Pharmaceuticals stocks

RPRX revenue $2.4BCORT revenue $761.0MLQDA revenue $158.0MPBH revenue $1.1BQUIT financialsHITI revenue $594.0METRA stockTRXB stockNSRX stockAll Medical - Pharmaceuticals stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
RTSN Overview RTSN Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.